Travel Clearance Assessment — 2026-05-27

Updated 2026-05-27 (same day): May 27 labs now confirmed. Projected ANC nadir has materialized: WBC 2400, ANC 1460. Hb paradoxically first normal (12.0). Travel status unchanged — NOT travel-suitable.

Summary

Current status is NOT travel-suitable without oncology clearance. Multiple concurrent contraindications exist across hematologic, infection-risk, and clinical stability domains.

Active Contraindications

1. Active Myelosuppressive Nadir (Confirmed — Critical)

Cycle 5 lineage cascade is fully documented and the WBC/ANC nadir is confirmed today (May 27):

• Hb 12.0 N — first normal hemoglobin since AML diagnosis (Nov 2025). Paradoxically normal while granulopoiesis is at nadir — classic dissociated lineage kinetics of Aza-Ven. Does NOT confer travel suitability; the neutropenia remains the operative contraindication.
• ANC 1460 — moderate neutropenia, confirmed nadir. Below the 1500 threshold for adequate neutrophil defense. Prior cycles have shown ANC recovery ~7–14 days post-nadir; estimated recovery June 2–7.
• WBC 2400 — leukopenia deepening; the concurrent ANC nadir indicates the absolute neutropenia is the active risk, not just leukopenia.
• Plt 107K — thrombocytopenic, stabilizing in the 103–117K range. Below optimal but not in the <50K danger zone.

2. Infection Risk Without Hospital Proximity

• On venetoclax + azacitidine — profound combined myelosuppression; venetoclax-specific risk of prolonged, severe neutropenia.
• No G-CSF support (pegfilgrastim discontinued Mar 30 due to bone pain). No rescue agent available at home.
• Acyclovir + posaconazole prophylaxis active, but these are prophylactic only — neutropenic fever requires IV antibiotics, hospital admission, and CBC monitoring q24–48h.
• Any travel that takes the patient >30–60 min from a hospital capable of managing febrile neutropenia is contraindicated.

3. Active Thrombocytopenia

• Plt 107K (May 27, stabilizing; nadir was 103K May 17). KIMS threshold for procedural safety is typically 50K; bleeding-concern threshold is <100K.
• Air travel: risk of DVT/venous stasis, pressure changes; not directly implicated at Plt 103K, but any ground-level fall, airport handling incident → elevated hemorrhage.
• Port in situ (placed 2025-12-09) — requires sterile access protocols not available outside specialized settings.

4. Anemia / Orthostatic Risk

• Hb 12.0 g/dL on May 27 — now normal (first normal since AML Dx). Anemia per se is no longer an active contraindication.
• However: 81F + pregabalin (CNS depression, fall risk) + active neutropenia + port in situ = multi-factorial fall and infection risk during transport.
• Falls risk assessment has never been formally documented (TUG absent from vault — see Hot).

5. Diabetes with Poor Glycemic Control

• Fructosamine 310 µmol/L (Apr 29) — high, indicating poor 1–2 week glucose control.
• Travel disrupts meal timing, metformin dosing schedule (TID), and degludec insulin timing.
• Hypoglycemia risk in transit is elevated with erratic food intake.

6. Medication Logistics

• Active regimen includes posaconazole (requires refrigeration if suspension form; food-dependent absorption), venetoclax (CYP3A4 interaction — grapefruit contamination risk in some settings), and acyclovir.
• A break or delay in posaconazole would remove the CYP3A4 inhibition that enables the venetoclax dose reduction strategy, potentially altering venetoclax exposure.
• Metformin contraindicated with IV contrast (relevant if any imaging needed at destination).

What Would Be Required for Travel Clearance

1. Oncology (Dr. Bijay) explicit clearance — Dr. Bijay must assess whether the patient is in the inter-cycle recovery window (not mid-nadir).
2. Post-nadir CBC — ANC ≥1500 (ideally ≥2000), Plt ≥75–100K, Hb ≥10 g/dL, and trending stable or improving.
3. Destination hospital availability — Pre-identified hospital at destination capable of managing febrile neutropenia, transfusion, and oncology emergencies.
4. Travel insurance with oncology coverage — Medical repatriation capability.
5. No active infection or fever — Any fever ≥38°C in this context is an oncologic emergency.
6. Medication supply — Full supply of all 13 active medications for duration + 7-day buffer.

Timing Context

As of 2026-05-27, the WBC/ANC nadir is confirmed (WBC 2400, ANC 1460). Based on 3-cycle lineage cascade pattern (Plt nadir → Hb nadir ~6d later → WBC/ANC nadir ~10d after Plt nadir), recovery typically follows over 7–14 days post-ANC nadir. Earliest plausible travel window: ~June 4–10, 2026 — contingent on serial CBC confirmation of ANC ≥1500–2000 and Plt ≥75–100K.

No travel should occur without fresh labs (within 48–72 h of departure) and explicit oncology clearance from Dr. Bijay.

Gaps Noted

• Exact Cycle 5 start date not in vault — Cycle 5 appointment/schedule not documented (persistent gap from Apr 29).
• No clinic note from May 2026 beyond lab reports — Dr. Bijay's current clinical assessment unknown.
• BP not measured (HTN on losartan monotherapy — unconfirmed cardiovascular stability).

Filed from query: "Based on current is it ok to travel" — 2026-05-27